Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers
Aberrant expression of RNA-binding motif protein 3 (RBM3) has been suggested as a prognostic biomarker in several malignancies.
Materials and methods
This study was performed to analyse the prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers (NSCLCs). Therefore, we took advantage of our tissue microarray (TMA) containing more than 600 NSCLC specimens.
While nuclear RBM3 staining was always high in normal lung tissue, high RBM3 staining was only seen in 77.1% of 467 interpretable non-metastatic NSCLCs. Reduced RBM3 staining was significantly associated with advanced pathological tumor stage (pT) in NSCLCs (p = 0.0031). Subset analysis revealed that the association between reduced RBM3 staining and advanced pT stage was largely driven by the histological subgroup of lung adenocarcinoma (LUACs) (p = 0.0036). In addition, reduced RBM3 expression predicted shortened survival in LUAC patients (p = 0.0225).
In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.
KeywordsRBM3 Lung adenocarcinoma Squamous cell lung carcinoma Large cell lung carcinoma Non-small-cell lung carcinoma Immunohistochemistry
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Lleonart ME (2010) A new generation of proto-oncogenes: cold-inducible RNA binding proteins. Biochimica et biophysica acta 1805:43–52Google Scholar
- Zhang H-T et al (2013) Differential expression of the RNA-binding motif protein 3 in human astrocytoma. Chin Med J 126:1948–1952Google Scholar
- Zhou R-B et al (2017) RNA binding motif protein 3: A potential biomarker in cancer and therapeutic target in neuroprotection. Oncotarget 8:22235–22250Google Scholar